Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhu, Mingyue ^a   Li, Wei ^a   Lu, Yan ^a   Dong, Xu ^a   Chen, Yi ^a   Lin, Bo ^a   Xie, Xieju ^a   Guo, Junli ^a   Li, Mengsen ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; APOPTOSOME; BIRC5 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN; PACLITAXEL; RAS PROTEIN;

APOPTOSIS; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSOMES; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PACLITAXEL; RAS PROTEINS;

EID: 84973345410     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26472     Document Type: Article

References (43)

1. Hu, P. et al. Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells. Mol Biol Rep. 41, 19-24 (2014).
2. Liu, K., Cang, S., Ma, Y. & Chiao, J. W. Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int. 13, 10 (2013).
3. Donehower, R. C. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Stem Cells 14, 25-28 (1996).
4. Gotoh, M. et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and desgamma-carboxyprothrombin. Jpn J. Clin Oncol. 33, 522-526 (2003).
5. Gao, P. et al. Hypoxia-inducible enhancer/alpha-fetoprotein promoter-driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. Cancer Sci. 99, 2209-2217 (2008).
6. Yang, X., Zhang, Y., Zhang, L. & Mao, J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 271, 281-293 (2008).
7. Zhang, H., Bai, Z., Chen, J., Wang, Z. & Li, J. Alpha-fetoprotein-specific transfer factors downregulate alpha-fetoprotein expression and specifically induce apoptosis in Bel7402 alpha-fetoprotein-positive hepatocarcinoma cells. Hepatol Res. 37, 557-567 (2007).
8. Ho, H. K. et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J. Hepatol. 50, 118-127 (2009).
9. Li, M. S. et al. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel 7402 cell line. World J. Gastroenterol. 8, 469-475 (2002).
10. Patt, Y. Z. et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer. 72, 2574-2582 (1993).
11. Li, M. et al. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J. Cancer. 124, 2845-2854 (2009).
12. Li, M. S. et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J. Gastroenterol. 11, 2564-2569 (2005).
13. Li, C. et al. Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of GADD153 in human hepatoma cell lines. Int J. Cancer. 130, 754-764 (2012).
14. Li, M. et al. Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett. 285, 190-199 (2009).
15. Li, M. et al. Alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett. 249, 227-234 (2007).
16. Chae, S., Kim, Y. B., Lee, J. S. & Cho, H. Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. Am J. Physiol Gastrointest Liver Physiol. 302, G1016-1024 (2012).
17. Jin, C. et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J. Cancer Res Clin Oncol. 136, 267-274 (2010).
18. Yan, H., Wang, S., Yu, H., Zhu, J. & Chen, C. Molecular pathways and functional analysis of miRNA expression associated with paclitaxel-induced apoptosis in hepatocellular carcinoma cells. Pharmacology. 92, 167-174 (2013).
19. Chen, L., Liu, Y., Wang, W. & Liu, K. Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy. Oncol Lett. 10, 77-84 (2015).
20. Chao, Y. et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 78, 34-39 (1998).
21. Chun, E. & Lee, K. Y. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 315, 771-779 (2004).
22. Sutter, A. P. et al. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J. Hepatol. 41, 799-807 (2004).
23. Gagandeep, S., Novikoff, P. M., Ott, M. & Gupta, S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett. 136, 109-118 (1999).
24. Lotem, J. & Sachs, L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene. 25, 7663-7672 (2006).
25. Oishi, N., Yamashita, T. & Kaneko, S. Molecular biology of liver cancer stem cells. Liver Cancer. 3, 71-84 (2014).
26. Oikawa, T. et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat Commun. 6, 8070 (2015).
27. Yang, T. & Rycaj, K. Targeted therapy against cancer stem cells. Oncol Lett. 10, 27-33 (2015).
28. Qiu, H., Fang, X., Luo, Q. & Ouyang, G. Cancer stem cells: a potential target for cancer therapy. Cell Mol Life Sci. 72, 3411-3424 (2015).
29. Justilien, V. & Fields, A. P. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 21, 505-513 (2015).
30. Adorno-Cruz, V. et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 75, 924-929 (2015).
31. Ji, J. et al. Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology. 62, 829-840 (2015).
32. Sell, S. Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol. 29, 161-180 (2008).
33. Yamashita, T. et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 57, 1484-1497 (2013).
34. Sasaki, N. et al. Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics. Cancer Lett. 308, 152-161 (2011).
35. Rhéaume, E. et al. The large subunit of replication factor C is a substrate for caspase-3 in vitro and is cleaved by a caspase-3-like protease during Fas-mediated apoptosis. EMBO J. 16, 6346-6354 (1997).
36. Jänicke, R. U., Ng, P., Sprengart, M. L. & Porter, A. G. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem. 273, 15540-15545 (1998).
37. Shin, S. et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 40, 1117-1123 (2001).
38. Fujita-Sato, S. et al. Enhanced MET translation and signaling sustains K-ras-driven proliferation under anchorage-ondependent growth conditions. Cancer Res. 75, 2851-2862 (2015).
39. Li, M. et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int J Cancer. 128, 524-532 (2011).
40. Zhu, M. et al. Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells. Oncotarget. 6, 12196-12208 (2015).
41. Takeyama, H. et al. Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases. World J. Surg Oncol. 5, 79 (2007).
42. Peng, Y. F. et al. α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. PLoS One. 8, e53072 (2013).
43. Lu, Y. et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J Cell Mol Med 20(3), 549-558 (2016).